Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Advanced HER2+Breast Cancer × 1 year × Clear all

Phase

Status

Active not recruiting 1

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Breast Neoplasms 2765 Neoplasms 2237 Carcinoma, Non-Small-Cell Lung 1682 Prostatic Neoplasms 1509 Colorectal Neoplasms 1224 Lung Neoplasms 1147 Multiple Myeloma 851 Neoplasm Metastasis 826 Leukemia, Myeloid, Acute 793 Pancreatic Neoplasms 768 Ovarian Neoplasms 723 Melanoma 710 Carcinoma, Hepatocellular 661 Recurrence 583 Brain Neoplasms 578 Squamous Cell Carcinoma of Head and Neck 575 Stomach Neoplasms 572 Head and Neck Neoplasms 517 Lymphoma 501 Glioblastoma 500 Uterine Cervical Neoplasms 478 Precursor Cell Lymphoblastic Leukemia-Lymphoma 471 Carcinoma, Renal Cell 451 Triple Negative Breast Neoplasms 447 Endometrial Neoplasms 428 Urinary Bladder Neoplasms 417 Colonic Neoplasms 416 Hematologic Neoplasms 412 Lymphoma, Non-Hodgkin 399 Sarcoma 386

Interventions

pertuzumab 1 Trastuzumab 1 Alpelisib 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT04208178 2026-02-02

EPIK-B2

Novartis

Phase 3 Active not recruiting

Advanced HER2+Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon ⚡